Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilationREDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation NASDAQ:LUNG (“Pulmonx” or the “Company”), a global leader in mini…